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OBJECTIVE—This report presents data from the Eunice Kennedy Shriver National Institute of
Child Health and Human Development Neonatal Research Network on care of and morbidity and
mortality rates for very low birth weight infants, according to gestational age (GA).
METHODS—Perinatal/neonatal data were collected for 9575 infants of extremely low GA (22–28
weeks) and very low birth weight (401–1500 g) who were born at network centers between January
1, 2003, and December 31, 2007.
RESULTS—Rates of survival to discharge increased with increasing GA (6% at 22 weeks and 92%
at 28 weeks); 1060 infants died at ≤ 12 hours, with most early deaths occurring at 22 and 23 weeks
(85% and 43%, respectively). Rates of prenatal steroid use (13% and 53%, respectively), cesarean
section (7% and 24%, respectively), and delivery room intubation (19% and 68%, respectively)
increased markedly between 22 and 23 weeks. Infants at the lowest GAs were at greatest risk for
morbidities. Overall, 93% had respiratory distress syndrome, 46% patent ductus arteriosus, 16%
severe intraventricular hemorrhage, 11% necrotizing enterocolitis, and 36% late-onset sepsis. The
new severity-based definition of bronchopulmonary dysplasia classified more infants as having
bronchopulmonary dysplasia than did the traditional definition of supplemental oxygen use at 36
weeks (68%, compared with 42%). More than one-half of infants with extremely low GAs had
undetermined retinopathy status at the time of discharge. Center differences in management and
outcomes were identified.
CONCLUSION—Although the majority of infants with GAs of ≥24 weeks survive, high rates of
morbidity among survivors continue to be observed.
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Over the previous 2 decades, the Eunice Kennedy Shriver National Institute of Child Health
and Human Development Neonatal Research Network (NRN) has monitored trends in
morbidity and mortality rates among very low birth weight (VLBW) infants born at the
university centers that constitute the NRN.1–6 Increased VLBW infant survival rates have
paralleled improvements in prenatal, obstetric, and neonatal care.7,8 NRN data suggest that a
plateau in VLBW infant survival rates might have been reached, despite increased use of
prenatal corticosteroid treatment, prenatal antibiotic treatment, and early neonatal surfactant
treatment.6 Previous NRN reports presented patient characteristics, interventions, and
outcomes according to birth weight (BW), with an upper limit of 1500 g. Such BW-specific
data may be skewed by more-mature infants with growth restriction. The aim of this study was
to evaluate management, hospital complications, and mortality rates among infants with
gestational ages (GAs) of 22 to 28 weeks who were born at NRN centers between 2003 and
2007.
METHODS
Study Population and Clinical Outcomes
Infants born alive at NRN centers in 2003–2007 with GAs of 22 0/7 to 28 6/7 weeks and BWs
of 401 to 1500 g were studied, including those with congenital anomalies. These infants were
part of the NRN VLBW registry.1–6
Research personnel collected maternal pregnancy/delivery data soon after birth and infant data
from birth to death, discharge/transfer, or 120 days of age (“status”). For infants with prolonged
hospitalizations, limited information was collected up to 1 year. Definitions for maternal and
infant characteristics were provided in a manual of operations. GA was determined as the best
obstetric estimate by using ultrasonography and/or the date of the last menstrual period.
Stoll et al. Page 2
Pediatrics. Author manuscript; available in PMC 2010 November 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Intrauterine growth restriction, defined as BW of <10th percentile for gender and GA, was
determined by using growth charts published by Alexander et al.9 Morbidities were defined in
earlier publications,1–6,10,11 including respiratory distress syndrome, bronchopulmonary
dysplasia (BPD), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL),
early-onset and late-onset sepsis, necrotizing enterocolitis, patent ductus arteriosus, and
retinopathy of prematurity (ROP). Respiratory distress syndrome was defined on the basis of
clinical features and oxygen or respiratory support for ≥6 of the first 24 hours.
Three definitions of BPD were used, namely, traditional BPD (supplemental oxygen use at
postmenstrual age [PMA] of 36 weeks); BPD determined by using the National Institutes of
Health Workshop severity-based diagnostic criteria,12 and BPD determined according to
physiologic definition.13 Surviving infants who were discharged or transferred before PMA
of 36 weeks were classified on the basis of their status at 36 weeks, if status information was
available, or oxygen use at discharge/transfer, if status information was not available. Unless
noted otherwise, BPD refers to the traditional definition.
Revisions to data collection in 2006 included questions about maternal chorioamnionitis,
placental pathologic conditions, nitric oxide use, and ibuprofen use and expanded data
collection on birth resuscitation and neurologic, pulmonary, and ophthalmologic outcomes. In
addition to ophthalmologic examination results and interventions, the following outcomes,
defined in the manual of operations, were recorded: favorable in both eyes, severe ROP in
either eye, or undetermined in either eye without severe ROP in either eye. Complete definitions
are included in a footnote to Table 6. The registry was approved by the institutional review
boards at each center.
Statistical Analyses
All infants were studied for assessment of maternal characteristics, neonatal demographic
features, interventions performed soon after birth, and survival. Infants who died at ≤12 hours
were excluded from analyses focused on morbidities diagnosed at >12 hours. For determination
of rates of survival without morbidity, morbidity was defined as severe IVH (≥grade 3), PVL,
BPD, necrotizing enterocolitis, ≥stage 3 ROP, or infection (early-onset sepsis, late-onset sepsis,
or meningitis).
Statistical significance for unadjusted comparisons was determined by using χ2 or Wilcoxon
tests. Logistic or linear regression models were used to assess associations with GA, with
adjustment for study center and infant BW, with statistical significance determined by using
Wald χ2 or F tests. Generalized logit regression models were used for comparisons involving
categorical variables with >2 levels.
Risk of death and changes in clinical practice during the study period were assessed by using
robust Poisson regression models14 to produce correct SEs for the estimated relative risks
(RRs). Additional adjustments for clustering according to center were not made because study
center was treated as a fixed effect in these models, which also included effects for BW and
GA. To assess linear trends, year was included as a continuous variable, with adjusted RRs for
the change per year being reported. Initial models included terms for interactions between each
GA and year, to assess whether yearly trends varied according to GA. Nonsignificant
interactions were removed, and the models were rerun.
Participating NRN Study Centers
The numbers of infants included from each center were as follows: University of Alabama,
805 infants; Brown University, 616 infants; University of California, San Diego, 528 infants;
Case Western Reserve University, 415 infants; University of Cincinnati, 974 infants; Duke
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University, 426 infants; Emory University, 516 infants; Indiana University, 720 infants;
University of Iowa, 99 infants; University of Miami, 515 infants; University of New Mexico,
97 infants; University of Rochester, 243 infants; Stanford University, 334 infants; University
of Texas Southwestern Medical Center at Dallas, 488 infants; University of Texas Health
Science Center at Houston, 765 infants; Tufts University, 137 infants; University of Utah, 269
infants; Wake Forest University, 465 infants; Wayne State University, 637 infants; Yale
University, 526 infants.
RESULTS
Study Group
A total of 9575 infants with GAs of 22 to 28 weeks and BWs of 401 to 1500 g were born at
NRN centers between January 1, 2003, and December 31, 2007, and are included in this study.
Overall, 25% of the cohort subjects were multiple births.
Maternal and Infant Characteristics, Delivery Room Interventions, and Early Deaths
Rates of prenatal steroid use increased with increasing GA, from 13% at 22 weeks to 53% at
23 weeks and 85% to 87% at 24 to 28 weeks (Table 1). Rates of prenatal antibiotic use were
lowest for mothers who delivered at 22 weeks (51%) and highest for those who delivered at
24 to 25 weeks (73%). Chorioamnionitis was documented more frequently in maternal records
and confirmed more commonly by placental histologic findings at lower GAs. Overall, 59%
of infants were born through cesarean section, with the steepest increase in cesarean section
delivery rates between GAs of 22 and 24 weeks (7% at 22 weeks and 60% at 24 weeks).
With adjustment for center and BW, there were no differences in racial distribution according
to GA (Table 2). Early neonatal interventions differed according to GA (Table 2). At 22 weeks,
only 19% of infants underwent intubation and ventilation in the delivery room. Intubation rates
increased to 68% at 23 weeks and 87% at 24 weeks and decreased at >24 weeks. Of 856 infants
who received resuscitation drugs and/or chest compressions, 96% also underwent intubation.
Rates of surfactant therapy increased from 17% at 22 weeks to 63% at 23 weeks and 90% at
24 weeks. The proportion of infants who died at ≤ 12 hours decreased with increasing GA,
from 85% at 22 weeks to 1% to 2% at 27 to 28 weeks (Table 3). Risk of early death was
significantly elevated for infants born at 22 to 24 weeks, compared with infants born at 28
weeks (22 weeks, adjusted RR: 15.76 [95% confidence interval [CI]: 10.13–24.52]; 23 weeks,
adjusted RR: 9.88 [95% CI: 6.48 –15.08]; 24 weeks, adjusted RR: 2.90 [95% CI: 1.90–4.43]),
but not for infants born at 25 to 27 weeks.
Changes in Clinical Practices
Rates of prenatal steroid use increased by ~1% per year during the study period, and rates of
cesarean section delivery increased by ~2% per year (Table 4). Rates of prenatal antibiotic use
decreased by ~3% per year. These trends did not vary according to GA (year-GA interaction:
for prenatal steroid therapy, P = .47; for cesarean section delivery, P = .37; for prenatal
antibiotic treatment, P=.66). Rates of endotracheal intubation in the delivery room and
surfactant therapy varied according to GA (year-GA interaction: P < .01 for each). Rates of
intubation and surfactant therapy decreased for infants born at 28 weeks. During the study
period, the proportion of infants receiving continuous positive airway pressure (CPAP) therapy
at 24 hours increased among infants of ≥24 weeks, as did the proportion of infants who never
underwent intubation. Although the adjusted RR for BPD decreased over time among infants
who survived to PMA of 36 weeks, the change was clinically insignificant.
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Neonatal Characteristics and Morbidities Among Infants Who Survived >12 Hours
Overall, 89% of infants born at GAs of 22 to 28 weeks survived >12 hours. Substantially more
early survivors born at 22 to 24 weeks received resuscitation efforts (intubation, drug treatment,
and/or chest compression) in the delivery room, compared with infants born at 22 to 24 weeks
who died at ≤12 hours (22 weeks, 90% vs 7%; 24 weeks, 91% vs 59%). Significant differences
in resuscitation efforts between those who survived >12 hours and those who did not were not
seen among infants with GAs of 25 to 27 weeks. Among infants born at 28 weeks, a smaller
proportion of those who survived >12 hours received resuscitation efforts in the delivery room,
compared with those who died within 12 hours (48% vs 65%; P =.05).
Infants at the lowest GAs were at the greatest risk for morbidities of prematurity (Tables 5 and
6). Overall, 93% infants experienced respiratory distress. Rates of mechanical ventilation at
24 hours decreased from 96% at 22 weeks to 40% at 28 weeks, and rates of CPAP therapy at
24 hours increased from 0% at 22 weeks to 3% at 23 weeks, 8% at 24 weeks, and 38% at 28
weeks. The risk of BPD was inversely related to GA at birth. Because of the inclusion of infants
with mild BPD (oxygen therapy for ≥28 days but use of room air at 36 weeks), more infants
were classified as having BPD with the new, severity-based, definition of BPD (new definition,
68%; traditional definition, 42%; physiologic definition, 40%).
Most infants who survived >12 hours underwent ≥1 cranial ultrasound evaluation within 28
days; 64% of results were normal (Table 6). Overall, 10% of sonograms indicated grade 1 IVH,
6% grade 2 IVH, 7% grade 3 IVH, 9% grade 4 IVH, 2% ventriculomegaly without IVH, and
2% other abnormalities. PVL was observed for 3% of infants with sonograms performed in
the first 28 days and 4% with sonograms performed after 28 days. Rates of abnormal ultrasound
findings decreased with increasing GA.
Sepsis was diagnosed more frequently at the lowest GA (rates of early-onset sepsis were 6%
at 22 weeks and 1% at 28 weeks, and rates of late-onset sepsis were 58% at 22 weeks and 20%
at 28 weeks); 11% of infants developed necrotizing enterocolitis (Table 6). Patent ductus
arteriosus was diagnosed for 46% of infants, of whom 71% were treated with indomethacin,
13% ibuprofen (2006–2007), and 27% surgical closure. Among 7313 infants who were still in
the hospital at 28 days, 94% underwent an ophthalmologic examination before hospital
discharge, death, or transfer. Of the 6866 with examination findings, 59% were diagnosed as
having ROP (96% at 22 weeks and 32% at 28 weeks), and 12% underwent treatment for ROP
(50% at 22 weeks and 2% at 28 weeks). A total of 2630 infants evaluated in 2006–2007 had
ROP outcomes recorded at the time of discharge or 120 days of age. Among those infants, 39%
had favorable outcomes, 7% had unfavorable outcomes with severe ROP requiring treatment,
and 53% had undetermined ROP outcomes (ie, had not reached the threshold for surgery or
were still immature and required further examination) (Table 6).
Survival and Morbidity Rates (All 9575 Infants)
Rates of survival to discharge increased with increasing GA, from 6% at 22 weeks to 92% at
28 weeks (72% overall) (Fig 1 and Table 3). Infants born at 22 to 23 weeks had >3 times the
risk of death, compared with infants born at 28 weeks (22 weeks, adjusted RR: 3.88 [95% CI:
3.18–4.73]; 23 weeks, adjusted RR: 3.56 [95% CI: 2.95–4.30]). RRs decreased but remained
significant for infants born at 24 to 27 weeks, compared with 28 weeks (24 weeks, adjusted
RR: 2.52 [95% CI: 2.10–3.04]; 27 weeks, adjusted RR: 1.23 [95% CI: 1.01–1.49]). Rates of
survival to discharge according to GA did not change during the study period (Table 4).
Neonatal morbidities occurred frequently among survivors. Rates of survival with morbidity
decreased from 100% at 22 weeks to 92% at 23 weeks, 91% at 24 weeks, 80% at 25 weeks,
66% at 26 weeks, 56% at 27 weeks, and 43% at 28 weeks. Infection and BPD were the most-
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frequent morbidities. Although unadjusted rates of survival without major morbidity seemed
unchanged, the adjusted RR for survival without morbidity increased over time (Table 4). The
median length of hospital stay among survivors was 84 days, and lengths of stay decreased
with increasing GA, from 141 days at 22 weeks to 63 days at 28 weeks (P <.001). PMA at
discharge decreased from 42 weeks for surviving infants born at GAs of 22 weeks to 37 weeks
for those born at 28 weeks (Fig 2).
DISCUSSION
Although VLBW infant mortality rates in the United States decreased substantially in the 1980s
and early 1990s,3–6, 15–18 most reports, including findings for this cohort, failed to demonstrate
further progress in reducing neonatal morbidity and mortality rates.6,16–19 In contrast, a
population cohort of all preterm infants born at GAs of <27 weeks in Sweden in 2004 –2007
demonstrated survival rates higher than rates reported for other countries or reported previously
for Sweden. 20 Our study reviewed neonatal morbidity and mortality rates for a large cohort
of extremely preterm infants, to evaluate changes in clinical practice and contemporary
outcomes at US academic centers. Although previous reports from the NRN used BW as the
reference for morbidity and survival rates, the current study assessed outcomes according to
GA. Appreciation of GA-based outcomes is particularly valuable for prenatal counseling and
physician/family decision-making.
The decisions to provide active obstetric care and to initiate neonatal intensive care for the
most-immature infants remain controversial. Center differences in obstetric/early neonatal
interventions were identified, but we did not collect sufficiently detailed information on
decision-making processes to help explain differences. In our cohort, rates of active obstetric
intervention, as indicated by prenatal steroid administration and cesarean section delivery,
increased markedly after 23 weeks of gestation. Prenatal steroid use was almost twice as
frequent for infants born at GAs of 24 to 28 weeks, compared with infants born earlier.
Similarly, rates of neonatal interventions and intensive care, measured as active resuscitation
with ventilation in the delivery room, increased substantially between 22 and 23 weeks (19%
vs 68%). Rates of death at ≤12 hours, which in part reflect willingness to provide intensive
care to the most-immature infants, decreased with increasing GA, from 85% of infants at 22
weeks to 2% of infants at 28 weeks.
In-hospital morbidity rates remain high among extremely preterm infants, and morbidities
contribute to adverse neurodevelopmental outcomes. The majority of infants studied
experienced a major complication during the initial hospitalization, with the risk of morbidity
being inversely related to GA at birth. Center differences in the proportions of infants with
specific morbidities were noted. At the lowest GAs (22–24 weeks), small numbers of infants
at some centers contributed to the variability. The registry does not collect data on the reasons
behind the choice of interventions for individual infants and has limited data on the severity
of illness at birth, information that might permit more-detailed evaluation and understanding
of center differences. Reducing the high rates of in-hospital morbidity among extremely low
GA infants who are provided ongoing intensive care remains a challenge for clinicians and
investigators.
To reduce rates of BPD, attention is being paid to avoidance of intubation, less prophylactic
use of surfactant, and alternative modes of respiratory support. Rates of endotracheal intubation
in the delivery room decreased in recent years among infants of >24 weeks, with a
corresponding increase in CPAP therapy use at 24 hours of life. At GA of 28 weeks, use of
surfactant decreased in the most-recent years. Furthermore, the proportion of infants who
survived >12 hours without ever undergoing intubation and ventilation increased with
increasing GA and more-recent year of birth. With substantially increased use of CPAP
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therapy, it was surprising that overall rates of BPD were unchanged, although the adjusted RR
for BPD decreased over the study period.
This is the first study to report ophthalmologic status as favorable, unfavorable, or
undetermined at the time of the last in-hospital examination. Although 7% of all infants had
severe ROP, the rate was 30% for infants with GAs of 22/23 weeks. Of concern, 53% of infants
had undetermined ophthalmologic status at the last examination before discharge. This finding
has implications for discharge planning and underscores the importance of a medical home, to
ensure careful ophthalmologic follow-up monitoring of these vulnerable infants after discharge
home or transport to a community hospital.
Although ours is not a population-based study, we included all extremely low gestation births
at 20 academic centers across the United States that together represent >110 000 live births
per year, an annual birth cohort equal in size to the Swedish national cohort described recently.
20 The rate of extremely low gestation birth was fivefold higher in our NRN cohort (~10 births
at <27 weeks per 1000 infants) than in the Swedish cohort (2.3 births at <27 weeks per 1000
infants). This remarkable difference may be explained in part by Sweden’s universal health
insurance, with free prenatal care and associated social services, as well as an ethnically more
homogeneous and somewhat older pregnant population. The high rates of prematurity in our
cohort underscore the importance of the current health care debate in the United States. Survival
rates for extremely low gestation infants born at NRN centers are lower than those reported
from Sweden. For nearly all infants in the Swedish cohort, GA was estimated on the basis of
ultrasound findings. The authors of the Swedish study noted that a limitation of the use of
ultrasonography to determine GA is that erroneously low GAs might be estimated for infants
with growth restriction. Given the decrease in mortality rates with increasing GA,
underestimation of GA by as little as 1 week might explain in part the difference in mortality
rates between the 2 cohorts. Greater use of prenatal steroid treatment at all GAs and of surfactant
therapy at 22 to 23 weeks also might have contributed to differences between the 2 cohorts.
During the 5-year study period, there was no substantial improvement in rates of survival to
discharge for extremely low gestation infants born at NRN centers. However, each additional
week of GA at birth had substantial survival advantage; the most marked changes were between
GAs of 22 and 25 weeks, with survival rates increasing from 6% to 72%. Furthermore, rates
of survival to discharge without major morbidities increased dramatically between 22 and 25
weeks, with continued steady improvement for each additional week of gestation. PMA at
discharge for VLBW infants, a proxy measure of length of stay and a reflection of the cost of
care, was inversely related to GA at birth. Each additional week of GA at birth reduced PMA
at discharge by almost 1 week and total length of hospital stay by ~2 weeks, a reflection of
both severity of illness and complications of prematurity among these very immature infants.
Although adjusted RRs for survival without morbidity increased over time, the burden of in-
hospital complications remained high. Retrospective analyses of center differences and
benchmarking studies to identify best performance have been unable to identify modifiable
practices that consistently improve outcomes, which underscores the need for hypothesis-
driven clinical trials to assess the efficacy of current neonatal interventions. 21–24 Clinicians
and investigators are challenged to identify and to test currently available interventions and
resources that yield consistently lower morbidity and mortality rates at some centers, so that
we can improve rates of survival without major morbidities and reduce long-term
neurodevelopmental impairments for all infants.
WHAT’S KNOWN ON THIS SUBJECT: The NICHD NRN has published periodic
evaluations of morbidity and mortality rates for VLBW infants. Increased VLBW survival
has paralleled improvements in prenatal, obsteric and neonatal care, but recent data suggest
that a plateau in survival may have been reached.
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WHAT THIS STUDY ADDS: This study is the first NRN study to report outcomes on
the basis of GA-specific information, which should be particularly valuable to obstetricians
and pediatricians as they counsel parents of high-risk infants.
ABBREVIATIONS
VLBW very low birth weight
BPD bronchopulmonary dysplasia
BW birth weight
CI confidence interval
GA gestational age
IVH intraventricular hemorrhage
ROP retinopathy of prematurity
RR relative risk
NICHD National Institute of Child Health and Human Development
NRN Neonatal Research Network
CPAP continuous positive airway pressure
PVL periventricular leukomalacia
PMA postmenstrual age
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FIGURE 1.
Survival to discharge according to GA among 9575 VLBW infants born in NICHD NRN
centers between January 1, 2003, and December 31, 2007. The thin lines indicate ranges across
centers.
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FIGURE 2.
Median length of hospitalization (in weeks) and median PMA at discharge (in weeks) according
to GA at birth among 6859 VLBW infants who were born in NICHD NRN centers between
January 1, 2003, and December 31, 2007, and survived to discharge.
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se
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 d
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m
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 d
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m
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63
1
N
 =
 1
47
8
   
La
te
-o
ns
et
 se
ps
is
, a
ll 
in
fa
nt
s w
ho
 su
rv
iv
ed
 >
72
 h
36
38
37
36
33
0.
98
 (0
.9
6–
1.
0)
  .
1
C
ra
ni
al
 so
no
gr
ap
hy
 p
er
fo
rm
ed
 w
ith
in
 2
8 
d 
af
te
r b
irt
h
N
 =
 1
66
0
N
 =
 1
70
8
N
 =
 1
74
9
N
 =
 1
64
6
N
 =
 1
49
7
   
Se
ve
re
 IV
H
, a
ll 
in
fa
nt
s w
ith
 so
no
gr
am
s
16
16
14
17
16
0.
96
 (0
.9
3–
1.
0)
  .
05
In
fa
nt
s w
ho
 u
nd
er
w
en
t c
ra
ni
al
 im
ag
in
g 
be
fo
re
 a
nd
/o
r a
fte
r 2
8 
d
N
 =
 1
66
5
N
 =
 1
71
4
N
 =
 1
75
2
N
 =
 1
65
1
N
 =
 1
50
0
   
PV
L,
 a
ll 
in
fa
nt
s w
ith
 im
ag
in
g 
fin
di
ng
s
4
5
5
4
5
0.
93
 (0
.8
7–
1.
0)
  .
06
Su
rv
iv
ed
 to
 P
M
A
 o
f 3
6 
w
k
N
 =
 1
42
6
N
 =
 1
45
5
N
 =
 1
48
3
N
 =
 1
42
1
N
 =
 1
28
0
   
B
PD
, i
nf
an
ts
 w
ho
 su
rv
iv
ed
 to
 P
M
A
 o
f 3
6 
w
k
43
42
40
43
43
0.
94
 (0
.9
2–
0.
95
)
<.
00
1
Su
rv
iv
ed
 to
 d
is
ch
ar
ge
N
 =
 1
38
5
N
 =
 1
40
3
N
 =
 1
44
5
N
 =
 1
38
3
N
 =
 1
24
3
   
Su
rv
iv
ed
 w
ith
ou
t m
or
bi
di
ty
b
   
  2
2 
w
k
0
0
0
0
0
   
  2
3 
w
k
14
10
3
5
9
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C
ha
ra
ct
er
is
tic
Pe
rc
en
t
A
dj
us
te
d 
R
R
(9
5%
 C
I)
P
20
00
3
(N
 =
 1
91
9)
20
04
(N
 =
 1
99
2)
20
05
(N
 =
 2
03
2)
20
06
(N
 =
 1
90
0)
20
07
(N
 =
 1
73
2)
   
  2
4 
w
k
5
10
10
8
11
   
  2
5 
w
k
22
20
21
17
20
   
  2
6 
w
k
32
38
34
31
34
   
  2
7 
w
k
44
44
46
42
44
   
  2
8 
w
k
58
55
62
55
54
   
  A
ll 
in
fa
nt
s w
ho
 su
rv
iv
ed
 to
 d
is
ch
ar
ge
37
37
38
35
36
1.
04
 (1
.0
2–
1.
06
)
<.
00
1
In
fo
rm
at
io
n 
w
as
 m
is
si
ng
 as
 fo
llo
w
s:
 p
re
na
ta
l s
te
ro
id
 tr
ea
tm
en
t, 
27
 in
fa
nt
s;
 p
re
na
ta
l a
nt
ib
io
tic
 tr
ea
tm
en
t, 
30
 in
fa
nt
s;
 ce
sa
re
an
 se
ct
io
n 
de
liv
er
y,
 9
 in
fa
nt
s;
 d
el
iv
er
y 
ro
om
 en
do
tra
ch
ea
l i
nt
ub
at
io
n,
 9
 in
fa
nt
s;
 su
rf
ac
ta
nt
th
er
ap
y,
 1
0 
in
fa
nt
s;
 n
ev
er
 in
tu
ba
te
d,
 3
 in
fa
nt
s;
 n
ec
ro
tiz
in
g 
en
te
ro
co
lit
is
, 1
 in
fa
nt
; C
PA
P 
th
er
ap
y,
 1
4 
in
fa
nt
s;
 la
te
-o
ns
et
 se
ps
is
, 2
 in
fa
nt
s;
 se
ve
re
 IV
H
, 9
 in
fa
nt
s;
 P
V
L,
 1
 in
fa
nt
; B
PD
, 4
2 
in
fa
nt
s;
 su
rv
iv
ed
 w
ith
ou
t
m
or
bi
di
ty
, 3
2 
in
fa
nt
s. 
R
R
s a
nd
 P
 v
al
ue
s w
er
e 
de
te
rm
in
ed
 fo
r t
he
 c
ha
ng
e 
pe
r y
ea
r f
ro
m
 a
 m
od
ifi
ed
 P
oi
ss
on
 m
od
el
 th
at
 in
cl
ud
ed
 e
ff
ec
ts
 fo
r s
tu
dy
 c
en
te
r, 
in
fa
nt
 B
W
 a
nd
 G
A
, a
nd
 y
ea
r a
nd
, w
he
re
 si
gn
ifi
ca
nt
,
ef
fe
ct
s f
or
 th
e 
ye
ar
-G
A
 in
te
ra
ct
io
n 
(d
el
iv
er
y 
ro
om
 in
tu
ba
tio
n,
 su
rf
ac
ta
nt
 th
er
ap
y 
an
d 
C
PA
P 
th
er
ap
y 
at
 2
4 
h)
. R
R
s a
re
 sh
ow
n 
fo
r a
ll 
in
fa
nt
s o
ve
ra
ll 
in
 c
as
es
 in
 w
hi
ch
 th
e 
ye
ar
-G
A
 in
te
ra
ct
io
n 
w
as
 n
ot
 si
gn
ifi
ca
nt
an
d 
se
pa
ra
te
ly
 fo
r i
nf
an
ts
 b
or
n 
at
 e
ac
h 
G
A
 in
 c
as
es
 in
 w
hi
ch
 th
e 
in
te
ra
ct
io
n 
w
as
 si
gn
ifi
ca
nt
. T
he
 y
ea
r-
G
A
 in
te
ra
ct
io
n 
co
ul
d 
no
t b
e 
as
se
ss
ed
 fo
r t
he
 c
at
eg
or
y 
of
 n
ev
er
 in
tu
ba
te
d 
be
ca
us
e 
of
 sm
al
l s
am
pl
e 
si
ze
s.
a N
ev
er
 u
se
d 
co
nv
en
tio
na
l o
r h
ig
h-
fr
eq
ue
nc
y 
ve
nt
ila
to
r o
r u
nd
er
w
en
t n
as
al
 sy
nc
hr
on
iz
ed
 in
te
rm
itt
en
t m
an
da
to
ry
 v
en
til
at
io
n.
b M
or
bi
di
tie
s i
nc
lu
de
d 
B
PD
, s
ev
er
e 
IV
H
, P
V
L,
 n
ec
ro
tiz
in
g 
en
te
ro
co
lit
is
, R
O
P 
st
ag
e 
≥3
, a
nd
 in
fe
ct
io
ns
 (e
ar
ly
-o
ns
et
 se
ps
is
, l
at
e-
on
se
t s
ep
si
s, 
or
 m
en
in
gi
tis
). 
Pr
op
or
tio
ns
 w
er
e 
de
te
rm
in
ed
 a
m
on
g 
su
rv
iv
or
s. 
O
f
th
e 
25
 su
rv
iv
in
g 
in
fa
nt
s b
or
n 
at
 G
A
 o
f 2
2 
w
ee
ks
, n
on
e 
su
rv
iv
ed
 w
ith
ou
t m
aj
or
 m
or
bi
di
ty
.
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TA
B
LE
 5
Pu
lm
on
ar
y 
M
or
bi
di
tie
s A
cc
or
di
ng
 to
 G
A
 fo
r V
LB
W
 In
fa
nt
s W
ho
 W
er
e 
B
or
n 
in
 N
R
N
 C
en
te
rs
 B
et
w
ee
n 
Ja
nu
ar
y 
1,
 2
00
3,
 a
nd
 D
ec
em
be
r 3
1,
 2
00
7,
 a
nd
Su
rv
iv
ed
 >
12
 H
ou
rs
 A
fte
r B
irt
h
C
ha
ra
ct
er
is
ti
%
 (R
an
ge
)
22
 w
k
(N
 =
 6
2)
23
 w
k
(N
 =
 4
96
)
24
 w
k
(N
 =
 1
22
3)
25
 w
k
(N
 =
 1
42
6)
26
 w
k
(N
 =
 1
53
0)
27
 w
k
(N
 =
 1
81
1)
28
 w
k
(N
 =
 1
96
7)
T
ot
al
(N
 =
 8
51
5)
R
es
pi
ra
to
ry
 d
is
tre
ss
 sy
nd
ro
m
ea
95
 (7
5–
10
0)
98
 (7
5–
10
0)
98
 (6
4–
10
0)
97
 (7
7–
10
0)
94
 (6
1–
10
0)
90
 (5
0–
10
0)
86
 (5
5–
10
0)
93
 (6
0–
99
)
Su
rf
ac
ta
nt
 th
er
ap
ya
97
 (5
0–
10
0)
97
 (9
0–
10
0)
95
 (8
3–
10
0)
90
 (7
2–
10
0)
86
 (5
8–
10
0)
78
 (4
3–
95
)
65
 (4
1–
86
)
82
 (6
4–
93
)
Pn
eu
m
ot
ho
ra
x
15
 (0
–4
0)
11
 (0
–3
3)
11
 (0
–2
3)
9 
(4
–2
0)
7 
(0
–1
5)
5 
(0
–1
4)
4 
(0
–9
)
7 
(3
–1
3)
Pu
lm
on
ar
y 
he
m
or
rh
ag
eb
16
 (0
–5
0)
15
 (0
–5
0)
13
 (6
–4
0)
10
 (3
–2
8)
7 
(2
–2
0)
4 
(0
–1
4)
3 
(0
–7
)
7 
(3
–1
8)
Po
st
na
ta
l s
te
ro
id
 tr
ea
tm
en
ta
15
 (0
–5
0)
18
 (0
–5
0)
20
 (0
–6
0)
14
 (0
–4
4)
9 
(0
–3
0)
6 
(0
–1
4)
2 
(0
–6
)
10
 (0
–2
4)
N
ev
er
 in
tu
ba
te
da
,c
0 
(0
–0
)
<1
 (0
–6
)
<1
 (0
–2
)
2 
(0
–8
)
5 
(0
–1
4)
12
 (0
–4
0)
23
 (6
–4
4)
9 
(2
–2
2)
R
es
pi
ra
to
ry
 su
pp
or
t a
t 2
4 
h 
fo
r i
nf
an
ts
 w
ho
 su
rv
iv
ed
 >
24
 h
N
 =
 5
5
N
 =
 4
71
N
 =
 1
19
2
N
 =
 1
41
4
N
 =
 1
52
0
N
 =
 1
80
4
N
 =
 1
96
2
N
 =
 8
41
8
   
C
on
ve
nt
io
na
l o
r h
ig
h-
fr
eq
ue
nc
y 
ve
nt
ila
tio
na
,d
96
 (0
–1
00
)
94
 (8
3–
10
0)
89
 (7
1–
10
0)
76
 (5
7–
95
)
61
 (4
3–
92
)
49
 (2
1–
74
)
40
 (2
0–
61
)
62
 (4
7–
83
)
   
N
as
al
 S
IM
V
b,
d
0 
(0
–0
)
<1
 (0
–6
)
2 
(0
–1
6)
3 
(0
–2
0)
3 
(0
–1
8)
2 
(0
–1
2)
3 
(0
–1
6)
3 
(0
–1
4)
   
C
PA
P 
th
er
ap
ya
,d
0 
(0
–0
)
3 
(0
–1
0)
8 
(0
–2
9)
18
 (5
–3
0)
30
 (5
–4
9)
36
 (1
2–
79
)
38
 (1
7–
66
)
26
 (8
–4
6)
   
U
se
 o
f o
xy
ge
n 
al
on
ea
,d
2 
(0
–1
00
)
1 
(0
–6
)
1 
(0
–7
)
2 
(0
–7
)
2 
(0
–1
3)
3 
(0
–1
0)
5 
(0
–1
5)
3 
(<
1–
9)
In
fa
nt
s w
ho
 su
rv
iv
ed
 to
 P
M
A
 o
f 3
6 
w
k
N
 =
 2
7
N
 =
 2
41
N
 =
 7
90
N
 =
 1
12
1
N
 =
 1
34
4
N
 =
 1
64
8
N
 =
 1
85
2
N
 =
 7
02
3
   
B
PD
 (o
xy
ge
n 
us
e 
at
 3
6 
w
k)
a,
e
85
 (0
–1
00
)
73
 (3
5–
10
0)
69
 (3
1–
10
0)
55
 (2
0–
10
0)
44
 (1
9–
10
0)
34
 (1
3–
76
)
23
 (9
–8
8)
42
 (2
0–
89
)
In
fa
nt
s i
n 
ho
sp
ita
l a
t P
M
A
 o
f 3
6 
w
k 
or
 d
is
ch
ar
ge
d/
tra
ns
fe
rr
ed
 a
t 3
3–
36
 w
k
N
 =
 2
7
N
 =
 2
31
N
 =
 7
74
N
 =
 1
08
8
N
 =
 1
28
4
N
 =
 1
56
5
N
 =
 1
73
9
N
 =
 6
70
8
   
Se
ve
rit
y-
ba
se
d 
B
PD
a,
f
   
  M
ild
 B
PD
15
 (0
–1
00
)
26
 (0
–5
0)
26
 (0
–6
7)
37
 (0
–6
2)
35
 (0
–5
8)
28
 (0
–5
2)
16
 (0
–3
5)
27
 (5
–3
8)
   
  M
od
er
at
e 
B
PD
30
 (0
–1
00
)
35
 (0
–1
00
)
34
 (0
–6
8)
29
 (9
–7
0)
26
 (5
–7
1)
20
 (4
–5
5)
15
 (0
–5
7)
23
 (8
–6
0)
   
  S
ev
er
e 
B
PD
56
 (0
–1
00
)
39
 (0
–1
00
)
37
 (0
–1
00
)
26
 (3
–8
6)
17
 (4
–4
4)
13
 (0
–3
0)
8 
(0
–2
9)
18
 (3
–4
0)
In
fa
nt
s b
or
n 
in
 2
00
6–
20
07
N
 =
 1
9
N
 =
 1
74
N
 =
 4
38
N
 =
 5
47
N
 =
 5
66
N
 =
 7
28
N
 =
 7
54
N
 =
 3
22
6
   
In
ha
le
d 
ni
tri
c 
ox
id
e 
tre
at
m
en
tb
,g
11
 (0
–5
0)
8 
(0
–5
0)
10
 (0
–5
4)
8 
(0
–2
7)
7 
(0
–2
5)
3 
(0
–1
2)
3 
(0
–1
4)
6 
(0
–1
9)
   
  I
nf
an
ts
 w
ho
 su
rv
iv
ed
 to
 P
M
A
 o
f 3
6 
w
k
N
 =
 9
N
 =
 8
3
N
 =
 2
74
N
 =
 4
22
N
 =
 4
82
N
 =
 6
50
N
 =
 6
91
N
 =
 2
61
1
   
  B
PD
 b
y 
ph
ys
io
lo
gi
c 
de
fin
iti
on
a,
h
89
 (5
0–
10
0)
70
 (0
–1
00
)
68
 (0
–1
00
)
55
 (1
9–
10
0)
44
 (6
–1
00
)
31
 (0
–1
00
)
22
 (0
–1
00
)
40
 (1
5–
82
)
R
an
ge
s a
re
 a
cr
os
s a
ll 
pa
rti
ci
pa
tin
g 
N
R
N
 c
en
te
rs
. P
ro
po
rti
on
s a
re
 a
m
on
g 
al
l i
nf
an
ts
 w
ho
 su
rv
iv
ed
 >
12
 h
ou
rs
, e
xc
ep
t a
s n
ot
ed
. I
nf
or
m
at
io
n 
w
as
 m
is
si
ng
 a
s f
ol
lo
w
s:
 re
sp
ira
to
ry
 d
is
tre
ss
 sy
nd
ro
m
e,
 5
 in
fa
nt
s;
su
rf
ac
ta
nt
 tr
ea
tm
en
t, 
7 
in
fa
nt
s;
 p
ul
m
on
ar
y 
he
m
or
rh
ag
e,
 2
 in
fa
nt
s;
 p
os
tn
at
al
 st
er
oi
d 
tre
at
m
en
t, 
41
 in
fa
nt
s;
 n
ev
er
 in
tu
ba
te
d,
 3
 in
fa
nt
s;
 v
en
til
at
or
 u
se
 at
 2
4 
ho
ur
s, 
13
 in
fa
nt
s;
 n
as
al
 sy
nc
hr
on
iz
ed
 in
te
rm
itt
en
t m
an
da
to
ry
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ve
nt
ila
tio
n 
at
 2
4 
ho
ur
s, 
14
 in
fa
nt
s;
 C
PA
P 
at
 2
4 
ho
ur
s, 
14
 in
fa
nt
s;
 o
xy
ge
n 
al
on
e 
at
 2
4 
ho
ur
s, 
14
 in
fa
nt
s;
 n
itr
ic
 o
xi
de
 u
se
, 1
 in
fa
nt
. P
 v
al
ue
s w
er
e 
de
te
rm
in
ed
 w
ith
 th
e 
W
al
d 
χ2
 te
st
 fo
r d
iff
er
en
ce
s a
cc
or
di
ng
 to
G
A
, w
ith
 a
dj
us
tm
en
t f
or
 c
en
te
r a
nd
 B
W
 o
r, 
fo
r n
as
al
 sy
nc
hr
on
iz
ed
 in
te
rm
itt
en
t m
an
da
to
ry
 v
en
til
at
io
n 
an
d 
in
ha
le
d 
ni
tri
c 
ox
id
e 
us
e,
 w
ith
 a
dj
us
tm
en
t f
or
 B
W
 o
nl
y.
 S
IM
V
 in
di
ca
te
s s
yn
ch
ro
ni
ze
d 
in
te
rm
itt
en
t
m
an
da
to
ry
 v
en
til
at
io
n.
a P
 ≤ 
.0
01
.
b P
 ≤ 
.0
5.
c N
ev
er
 u
se
d 
co
nv
en
tio
na
l o
r h
ig
h-
fr
eq
ue
nc
y 
ve
nt
ila
to
r o
r u
nd
er
w
en
t n
as
al
 sy
nc
hr
on
iz
ed
 in
te
rm
itt
en
t m
an
da
to
ry
 v
en
til
at
io
n.
d P
ro
po
rti
on
s a
m
on
g 
in
fa
nt
s w
ho
 su
rv
iv
ed
 >
24
 h
ou
rs
 a
fte
r b
irt
h.
 U
se
 o
f o
xy
ge
n 
al
on
e 
at
 2
4 
ho
ur
s w
as
 d
ef
in
ed
 a
s r
ec
ei
vi
ng
 su
pp
le
m
en
ta
l o
xy
ge
n 
w
ith
ou
t c
on
ve
nt
io
na
l o
r h
ig
h-
fr
eq
ue
nc
y 
ve
nt
ila
tio
n,
 n
as
al
sy
nc
hr
on
iz
ed
 in
te
rm
itt
en
t m
an
da
to
ry
 v
en
til
at
io
n,
 o
r C
PA
P 
th
er
ap
y.
e P
ro
po
rti
on
s a
m
on
g 
in
fa
nt
s w
ho
 su
rv
iv
ed
 to
 P
M
A
 o
f 3
6 
w
ee
ks
 a
nd
 h
ad
 n
on
m
is
si
ng
 o
ut
co
m
e 
da
ta
 (N
 v
al
ue
s s
ho
w
n)
. B
PD
 c
ou
ld
 n
ot
 b
e 
de
te
rm
in
ed
 fo
r 4
2 
in
fa
nt
s.
f P
ro
po
rti
on
s a
m
on
g 
in
fa
nt
s w
ho
 w
er
e 
st
ill
 in
 th
e 
ho
sp
ita
l a
t P
M
A
 o
f 3
6 
w
ee
ks
 o
r, 
if 
di
sc
ha
rg
ed
 o
r t
ra
ns
fe
rr
ed
 b
ef
or
e 
36
 w
ee
ks
, w
er
e 
in
 th
e 
ho
sp
ita
l f
or
 ≥2
8 
da
ys
 a
nd
 u
nt
il 
PM
A
 o
f 3
3 
w
ee
ks
. N
 v
al
ue
s a
re
 sh
ow
n
fo
r i
nf
an
ts
 w
ith
 n
on
m
is
si
ng
 o
ut
co
m
e 
da
ta
. S
ev
er
ity
-b
as
ed
 B
PD
 c
ou
ld
 n
ot
 b
e 
de
te
rm
in
ed
 fo
r 6
8 
in
fa
nt
s. 
M
or
e 
in
fo
rm
at
io
n 
ab
ou
t s
ev
er
ity
-b
as
ed
 B
PD
 is
 p
re
se
nt
ed
 in
 th
e 
te
xt
.
g P
ro
po
rti
on
s a
m
on
g 
in
fa
nt
s b
or
n 
in
 2
00
6–
20
07
.
h P
ro
po
rti
on
s a
m
on
g 
in
fa
nt
s b
or
n 
in
 2
00
6–
20
07
 w
ho
 su
rv
iv
ed
 to
 P
M
A
 o
f 3
6 
w
ee
ks
 a
nd
 h
ad
 n
on
m
is
si
ng
 o
ut
co
m
e 
da
ta
 (N
 v
al
ue
s s
ho
w
n)
. B
PD
 a
cc
or
di
ng
 to
 th
e 
ph
ys
io
lo
gi
c 
de
fin
iti
on
 c
ou
ld
 n
ot
 b
e 
de
te
rm
in
ed
fo
r 9
0 
in
fa
nt
s. 
In
fo
rm
at
io
n 
on
 h
ow
 B
PD
 w
as
 d
et
er
m
in
ed
 a
cc
or
di
ng
 to
 th
e 
ph
ys
io
lo
gi
c 
de
fin
iti
on
 is
 p
re
se
nt
ed
 in
 th
e 
te
xt
.
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t d
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t d
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t d
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at
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, d
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 m
at
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ex
am
in
at
io
ns
, a
cu
te
 R
O
P 
of
 st
ag
e 
1 
or
 2
 in
 z
on
e 
II
I i
n 
2 
co
ns
ec
ut
iv
e 
ex
am
in
at
io
ns
, o
r R
O
P
in
 z
on
e 
II
 o
r z
on
e 
II
I b
ut
 d
et
er
m
in
ed
 to
 b
e 
cl
ea
rly
 re
gr
es
si
ng
; (
2)
 u
nf
av
or
ab
le
, d
ef
in
ed
 a
s s
ev
er
e 
R
O
P 
on
 th
e 
ba
si
s o
f o
ne
 o
f t
he
 fo
llo
w
in
g 
in
 e
ith
er
 e
ye
: r
ec
ei
ve
d 
su
rg
ic
al
 tr
ea
tm
en
t f
or
 R
O
P,
 m
et
 c
rit
er
ia
 fo
r
un
de
rg
oi
ng
 su
rg
er
y,
 o
r r
et
in
al
 d
et
ac
hm
en
t r
es
ul
tin
g 
fr
om
 R
O
P;
 o
r (
3)
 u
nd
et
er
m
in
ed
 o
ut
co
m
e,
 d
ef
in
ed
 a
s o
ne
 o
f t
he
 fo
llo
w
in
g 
in
 e
ith
er
 e
ye
: i
m
m
at
ur
e 
ve
ss
el
s i
n 
zo
ne
 I 
or
 z
on
e 
II
, i
m
m
at
ur
e 
ve
ss
el
s r
ea
ch
in
g
zo
ne
 II
I i
n 
an
y 
si
ng
le
 e
xa
m
in
at
io
n,
 st
ag
e 
1 
or
 2
 R
O
P 
in
 z
on
e 
II
I a
t a
ny
 si
ng
le
 e
xa
m
in
at
io
n,
 st
ag
e 
2 
or
 3
 R
O
P 
in
 z
on
e 
II
 o
r I
II
 n
ot
 re
gr
es
si
ng
, o
r a
ct
iv
e 
R
O
P 
in
 z
on
e 
I o
r z
on
e 
II
. D
at
a 
on
 o
ut
co
m
e 
at
 st
at
us
 w
as
m
is
si
ng
 fo
r 1
3 
in
fa
nt
s.
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